Diabetic nephropathy: The proteinuria hypothesis

被引:80
作者
Williams, ME [1 ]
机构
[1] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA
关键词
diabetic nephropathy; proteinuria; clinical trials; hypertension; angiotensin; converting enzyme inhibitors; angiotensin receptor blockers;
D O I
10.1159/000084286
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: Proteinuria, nearly a universal finding in progressive kidney disease, has been the subject of frequent recent analyses in the renal literature. Proteinuria is a hallmark of diabetic nephropathy: microalbuminuria is the principal early predictor for progression of diabetic glomerulopathy, and proteinuria may be viewed as a measure of the severity and promoter of progression of nephropathy. Methods: This article critically reviews for the first time the full scope of diabetic proteinuria - complex molecular mechanisms, natural history, and analysis of treatment trials - in order to address the validity of 'the proteinuria hypothesis', i.e., that diabetic proteinuria is a modifiable determinant of renal progression. This hypothesis is analyzed in detail, including recent studies on the primary therapy of diabetic nephropathy, renin-angiotensin blockade. Results: As fully developed, this hypothesis consists of three postulates: that higher amounts of proteinuria predict progressive loss of function, that proteinuria reduction correlates with slowing progression, and that proteinuria is a surrogate endpoint for clinical trials. The latter postulate has not before been adequately linked to growing information about the first two postulates as they apply to diabetic kidney disease. Conclusion: While diabetic nephropathy is a disease model for the potential use of proteinuria as a surrogate marker for renal progression, this shift in perspective will require prospective data from additional clinical trials, particularly of non-renin-angiotensin blocking drugs, to be complete. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:77 / 94
页数:18
相关论文
共 178 条
[1]   Kidney and hypertension [J].
Adamczak, M ;
Zeier, M ;
Dikow, R ;
Ritz, E .
KIDNEY INTERNATIONAL, 2002, 61 :S62-S67
[2]   Diabetic nephropathy: Linking histology, cell biology, and genetics [J].
Adler, S .
KIDNEY INTERNATIONAL, 2004, 66 (05) :2095-2106
[3]   ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1 [J].
Amann, B ;
Tinzmann, R ;
Angelkort, B .
DIABETES CARE, 2003, 26 (08) :2421-2425
[4]  
Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213
[5]  
Andersen S, 2000, KIDNEY INT, V58, P2129
[6]   Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy [J].
Andersen, S ;
Jacobsen, P ;
Tarnow, L ;
Rossing, P ;
Juhl, TR ;
Parving, HH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (02) :293-297
[7]  
Appel Gerald, 1999, Journal of the American Society of Nephrology, V10, p153A
[8]   Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy [J].
Baelde, HJ ;
Eikmans, M ;
Doran, PP ;
Lappin, DWP ;
de Heer, E ;
Bruijn, JA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) :636-650
[9]   Effects of an ACE inhibitor calcium antagonist combination on proteinuria in diabetic nephropathy [J].
Bakris, GL ;
Weir, MR ;
DeQuattro, V ;
McMahon, FG .
KIDNEY INTERNATIONAL, 1998, 54 (04) :1283-1289
[10]   Differential effects of calcium antagonist subclasses on markers of nephropathy progression [J].
Bakris, GL ;
Weir, MR ;
Secic, M ;
Campbell, B ;
Weis-McNulty, A .
KIDNEY INTERNATIONAL, 2004, 65 (06) :1991-2002